Compare BioNTech SE - ADR (BNTX) vs Expedia Group Inc (EXPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Expedia Group Inc — how do they compare? BioNTech SE - ADR trades at $91.5 (market cap $22.86B), while Expedia Group Inc trades at $266.78 (market cap $31.96B). The key difference: Expedia Group Inc is the larger of the two by market cap, and Expedia Group Inc pays a 0.66% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | EXPE | |
|---|---|---|
Market Cap | $22.86B | $31.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $301.31 |
52-Week Low | $83.89 | $178.06 |
Enterprise Value | $6.53B | $30.87B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Expedia Group (EXPE) trades at $265.63, down 1.92% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $287.90 implying 8.4% upside. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.96 surpassing expectations of $1.41. Revenue grew to $14.73B in 2025, and net income reached $1.29B, supported by a high gross profit margin of 90.27%. Recent developments include a strategic partnership with Allegiant Travel and upcoming Q2 2026 earnings on August 5, 2026.
The outlook for EXPE is positive, driven by earnings momentum, strategic partnerships, and analyst optimism, but risks include travel sector volatility and high debt levels. The stock presents a growth opportunity with reasonable valuation multiples (P/E 23.47, EV/EBITDA 9.99), though investors should monitor competitive pressures and macroeconomic impacts on travel demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →
